Just The Tonix: New York Biotech Has Breakthrough Drug For PTSD
Executive Summary
Tonix Pharmaceuticals has won a breakthrough therapy designation this month for its post-traumatic stress disorder drug – the most advanced product in development specifically for the condition and potentially the first ever to market targeting PTSD as its lead indication.
You may also be interested in...
Eight Pivotal Trial Read-Outs Expected In Q3
A number of pivotal studies are expected to report top-line data in the third quarter. Here, with the help of Informa Pharma's Biomedtracker, we take a look at eight of those likely to be major catalysts for their sponsors.
Keeping Track: US FDA Approves Spinraza And Rubraca, Delays Ocrevus; Plus Submissions Galore
The latest drug development news and highlights from our FDA Performance Tracker.
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.